GCP
BBNX

GSA Capital Partners’s Beta Bionics BBNX Stock Holding History

GSA Capital Partners’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,744
Closed -$571K – 2245
2025
Q4 		$571K Buy
18,744
+3,888
+26% +$104K 0.05% 720
2025
Q3 		$295K Buy
+14,856
New +$261K 0.02% 1209

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GSA Capital Partners's BBNX Position: Q1 2026 in Review

GSA Capital Partners sold out of Beta Bionics (BBNX) in Q1 2026, closing a stake of 18,744 shares — an estimated $571K sold.

GSA Capital Partners first reported a position in BBNX in Q3 2025 and held it in 2 quarters. The position peaked at $571K in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • GSA Capital Partners reported no remaining Beta Bionics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 18,744 Beta Bionics shares in Q1 2026, an estimated $571K.
  • GSA Capital Partners first reported a position in Beta Bionics in Q3 2025 and held it in 2 quarters.
  • GSA Capital Partners's Beta Bionics position peaked at $571K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.